Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2019/20 Earnings Presentation
73 slides from Coloplast A/s Class B's earnings presentation, February 2020
Slide 1: Making it easier to get back on track
Making it easier to get back on track It took a while but now I have taken back control. I’m trying new things, pushing my limits again. Alessia Leading intimate healthcare Roadshow presentation Q1 2019/20 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid start to the year with 8% organic growth in Q1 and guidance maintained
Solid start to the year with 8% organic growth in Q1 and guidance for 2019/20 maintained Revenue growth Q1 2019/20 Highlights • Organic growth of 8% (9% reported growth in DKK) driven by solid Reported revenue (DKKm) +8% momentum across all business areas and geographies Organic growth • Solid quart
Slide 4: Solid growth across all business areas and geographical regions
Solid growth across all business areas and geographical regions Q1 19/20 revenue by business area Q1 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 1,907 9%
Slide 5: Ostomy Care grew 9% organically in Q1 2019/20
Ostomy Care grew 9% organically in Q1 2019/20, positively impacted by Emerging markets and China in particular Ostomy Care performance Comments • Q1 organic growth of 9% (reported growth 10%) 10 • Growth driven by China, US and UK 9 9 9 • Solid quarter for Emerging markets driven by China, Latin 8 8
Slide 6: Continence Care grew 6% organically in Q1 2019/20
Continence Care grew 6% organically in Q1 2019/20, negatively impacted by the French price reform Continence Care performance Comments 10 10 • Q1 organic growth of 6% (7% reported growth) 9 9 • Q1 organic growth was driven by SpeediCath® intermittent catheters 8 8 and Peristeen®, mainly in the UK an
Slide 7: Interventional Urology grew 9% organically in Q1
Interventional Urology grew 9% organically in Q1, driven by both Men’s and Women’s health Interventional Urology performance Comments • Q1 organic growth of 9% (12% reported growth) 14 14 14 • Growth continues to be driven by the US 12 • Continued solid growth in sales of Titan® penile implants in t
Slide 8: Wound Care grew 8% in Q1 2019/20
Wound Care grew 8% in Q1 2019/20 driven by the Biatain® Silicone portfolio in Europe Wound & Skin Care performance Comments • Q1 organic growth of 10% in Wound & Skin Care (11% reported growth) • Organic growth of 8% for Wound Care in isolation in Q1 11 11 11 11 • Growth continues to driven by the B
Slide 9: Q1 2019/20 reported revenue grew 9% driven by organic growth of 8%
Q1 2019/20 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • Q1 2019/20 reported revenue increased by DKK 391m (DKKm) or 9% compared to Q1 2018/19 46 4,712 • The majority of growth was driven by organic growth 345 contributing DKK 345m or 8% to reported rev
Slide 10: EBIT grew 13% in Q1 2019/20
EBIT grew 13% in Q1 2019/20 Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year 0.6 0.0 31.2 • Positive impact from operating leverage driven by revenue growth, ongoing efficiency improvements, GOP4 and the closure of the 1.0 Thisted factory in June 2019 0.6 •
Slide 11: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments • Free cash flow in Q1 2019/20 was DKK 816m, up 24% compared to DKK 658m in Q1 2018/19 98 99 98 98 • Adjusted for the positive impact of DKK 47m related to the 92 93 reclassification of lease payments following the adopt
Slide 12: Unchanged guidance for FY 2019/20
Unchanged guidance for FY 2019/20 Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • Stable growth trends across regions and business areas • Up to 1% negative price pressure from reforms in France, Holland and Switzerland Sales growth 7-8% 7-8% • Approx. half of 9% price cut in Chronic Care
Slide 13: Making it easier to be yourself
Making it easier_ to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Coloplast Capital Market Day 2020 24 June 2020 in Copenhagen – SAVE THE DATE! The event is intended to give institutional investors and eq
Slide 14: Leading intimate healthcare: Introduction to Coloplast
Leading intimate healthcare Introduction to Coloplast
Slide 15: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2018/19 by segment Group revenue 2018/19 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 36% #1 DKK DKK 17.9bn #1 Other 17.9bn European developed markets markets 59
Slide 16: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 17: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 18: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 19: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 13-14bn 12-13bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in % Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% regi
Slide 20: Building the consumer healthcare company of the future
We are building what we believe is the consumer healthcare company of the future Superior Clinical Consumer Payer products & preference preference preference innovation Care, DtC & Direct Data and digital tools Page 20
Slide 21: LEAD20 strategy across 4 major themes
Coloplast’s LEAD20 strategy will drive revenue and earnings growth across 4 major themes 1 Superior products & innovation 2 Unique user focused market approach 3 Unparalleled efficiency 4 Strong leadership development Page 21
Slide 22: Long-term guidance for the LEAD20 strategy period
Long-term guidance for the LEAD20 strategy period aimed at accelerating growth and long-term value creation Revenue growth EBIT margin annual organic constant currencies 7–9% >30% Page 22
Slide 23: Balanced investment strategy to fuel growth
To fuel growth & sustain long-term competitive advantage, our investment strategy has a balanced approach Up to 2% of sales invested annually across… …functions …geographies …and time horizons 15/16-18/19 15/16-18/19 Short term: Sales force, marketing and infrastructure • Optimize and expand our com
Slide 24: Global Coloplast Care and DtC presence
Our global Coloplast Care and DtC presence enables us to support users across countries and business areas Over 1M consumers in our database Over 1M conversations with users across the globe Over 30 countries with a consumer setup New Bowel Care program implemented in 2018 Coloplast Care & DTC offer
Slide 25: Clinical Performance Program to tackle the biggest issues users face
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 26: Digitalization of new products
Through digitalization of new products, we will take the next step towards our mission of making life easier for our users Digitalization in product development as first important milestone Payers Digitalization • We have a mission of making life easier Direct for people with intimate healthcare Glo
Slide 27: Burden of illness study in Germany shows significant payer costs
Example: Results from a burden of illness study in Germany show significant payer costs linked to ostomates Data Total cost per year Total cost split ostomates(1) EUR Inpatient Stoma products German claims database Colostomy, ileostomy and nursing 2.5m beneficiaries x3 and urostomy Outpatient Other
Slide 28: Global Operation Plan 4 supports LEAD20
Global Operation Plan 4 aims to support LEAD20 through continued unparalleled efficiency and financial discipline Global Operations Plan 4 1. Reduction of manufacturing in Denmark EBIT margin contribution, bps Manufacturing FTE’s in Denmark, Ultimo FY GOP 3 GOP 4 700 600 50 500 375 21% 225 100 Salar
Slide 29: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross margin development, in % of revenue Cost item Development, in % of revenue 0.5%-points 28.5 28.1 28.1 28.7 29.0 28-30 Distribution 68.5 68.3 68.1 67.3 67.7 - 0.1%-points 4.3
Slide 30: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% IT infrastructure Finance/ Master Data Global Business & support accountin
Slide 31: Continue to deliver strong free cash flows
We will continue to deliver strong and attractive free cash flows … Taxation Net working capital CAPEX(2) Reported tax rate, % Net working capital in % revenue Depreciation in % of revenue CAPEX DKKm CAPEX in % of revenue 4.4 28 24 24 25 24 3.8 4-5% 23 24 23 23 23 23 23 2.5 2.8 649 685 669 690 617 1
Slide 32: Attractive cash returns despite large investments
…and continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareholde
Slide 33: Key highlights from 2018/19 Corporate Responsibility initiatives
Key highlights from 2018/19 Corporate Responsibility initiatives Empowering People Acting respectfully Minimising footprint Our Access to Healthcare programme has New target to increase share of diverse teams Achieved 100% electricity from supported 62 projects since 2007. (gender, generation, natio
Slide 34: Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... 31% Comments • Stable market trends in our Chronic Care business • Strong Coloplast Care retention program and innovative DtC 10% activities 8% 9% • Increased focus on growing the business outside Europe • Ad
Slide 35: Appendices
Leading intimate healthcare Appendices
Slide 36: The Coloplast share (COLO'B-KO)
The Coloplast share (COLO’B-KO) Share Capital Ownership Coloplast share listed on Nasdaq Copenhagen since 1983 ~190 billion DKK (~28 billion USD) market cap @ ~875 DKK per 10% share (incl. A shares) 5% 2% Two share classes: 46% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (fre
Slide 37: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a combination of dividends and share buy- 0.1x 0.1x 0.1x -0.3x -0.2x backs • Interest bearing debt will be raised in connection with a major acquisition or other special
Slide 38: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 31.9 32.7 32.3 36.6 36.3 31.7 35.7 31.8 34.7 34.6 28.1 28.7 29.0 30.0 28.1 25.2 23.8 23.4 23.6 22.4 3.8 4.0 4.0 4.2 3.6 4.7 4.4 4.4 4.1 3.8 3.5 3.7 3.9 3.9 3.6 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Admin-to-S
Slide 39: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 9 7,166 10 6,291 6,643 13 5,935 8 12 9 9 10 10 10 8 6 9 7 7 10 6 10 7 67 9 9 5 6 1,907 1,740 1,970 1,497 1,641 535 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Continence Care Wound & Skin Care 6
Slide 40: Coloplast revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 9,941 10,573 9,213 9,394 15 16 13 8 11 8 11 6 5 6 6 2,744 3,642 3,791 4,380 10 3,177 5 1,178 4 2 5 6 6 4 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17(1) 17/18 18/19 YTD 19/20 Emerging Markets Coloplast group 17,939
Slide 41: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care2 Ostomy and Continence Care 60 39 38 39 39 40 39 57 58 57 37 37 38 55 34 2,083 2,047 197 1,886 1,928 1,901 187 194 177 170 235 250 228 225 201 Q1 18/19 Q2 18/19 Q3 18/19 Q4 18/19 Q1 1
Slide 42: Exchange rate exposure FY 2019/20 and hedging policy
Exchange rate exposure FY 2019/20 and hedging policy Revenue FX exposure 2019/20(1) 12 months exposure from 10% initial exchange rate drop(1) Other 15% -390 USD -170 EUR CNY, JPY, AUD, BRL & ARS 12% 39% -270 GBP -170 HUF 0 14% 110 GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 43: Mesh litigation timeline
Mesh litigation timeline Jan. 31, 2019: Verdict vs Ethicon PA State Court: USD 41M Jan. 21, 2020: Dec. 14, 2017: Verdict for Ethicon April 28, 2017: (DKK 354.3M) Sept. 9, 2014: Verdict vs Ethicon FL Federal Court: Verdict vs Ethicon NJ State Court: Verdict vs BSC Dec. 24, 2015: PA State Court: USD 1
Slide 44: US Mesh litigation – Overview of current financial impact
US Mesh litigation – Overview of current financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 1,472 Special items -1,000 -3,000 - 750 0 0
Slide 45: Health reform landscape
Health reform landscape Europe Rest of World • France: Reimbursement pressure on OC, CC and WC • U.S.: Healthcare reform implementation ongoing • Greece: Reimbursement pressure on all BAs • Argentina: Macroeconomic challenges • Germany: Reimbursement pressure on OC and CC • Brazil: Macroeconomic and
Slide 46: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance for in excess of 500,000 enrolled consumers We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content
Slide 47: With our DtC marketing program we reach into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 47
Slide 48: The generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Payer Reimbursement price Distribution Prescription & Insurance Consumer $ Product DtC Marketing • Campaigns • Community • Relationships • Information Coloplast Page 48
Slide 49: Interventional Urology remains core to the Coloplast mission
Interventional Urology remains core to the Coloplast mission and value creation agenda Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 18/19 growing 3-5% annually 11% Coloplast position ENDOUROLOGY MEN’S HEALTH WOMEN’S HEALTH SPECIALTY INTERVENTIONS of
Slide 50: Interventional Urology is a DKK 12-13bn market growing 3-5% annually
Interventional Urology is a DKK 12-13bn market growing 3-5% annually Business Area Market Dynamics Market Size (DKKbn) Market growth ~5 • Portfolio breadth increasingly valued Endourology ~5% • Single-use visualization significant opportunity 5 ~3 • Penile implant market responding to patient awaren
Slide 51: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 52: Interventional Urology competitive overview
Interventional Urology competitive overview Market presence Company Men’s Health Women’s Health Endourology Specialty Interventions / Page 52
Slide 53: The global AWC market remains large and growing
The global AWC market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and continues to grow across all regions categories and main growth contributors Market size in DKKbn RoW Silicone Foams Silicone Foam
Slide 54: In Wound Care we are progressing with our current strategy
In Wound Care we are progressing with our current strategy 1 Shape the standard Endorsements Publications Build a strong product 2 PIP portfolio 3 Accelerate in EU Ramp-up Strengthen position 4 in the US New structure New management New investment plan Secure leading position 5 in China Revised targ
Slide 55: US Ostomy Care: gaining share in acute, focus on home health
In US Ostomy Care, we continue to gain share in acute and have increased our focus on the home health channel US Ostomy patient pathway Continuing to gain share in the acute channel Patients +7 pts. Hospital 3-5 days 15/16 16/17 17/18 Recent acute contract wins PAC / HHA(1) ~75% of hospital >60 days
Slide 56: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 57: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products Brava® is a range of ostomy supporting products • Market size of DKK 2-3bn designed to reduce leakage or care for skin, to make • Market growth of 6-8% • Market share 30-35% Brava® Protective Seal our end-users feel secure.
Slide 58: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 59: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Faecal incontinence + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population + New devices addressing the many • Spinal Cord Injured, SCI • Spina Bifida, SB unmet needs • Multiple Sclerosi
Slide 60: Introducing Interventional Urology
Introducing Interventional Urology Treatment (surgical) of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Cus
Slide 61: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Wound Care other Customer groups Contract manufacturing & call points Hospitals Biatain® Silicone, incl. Sizes
Slide 62: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 63: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 64: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology Marketing Marketing Marketing Sales R&D Operations Sales Regions Sales Regions R&D Global Operations Global Busi
Slide 65: Coloplast Executive Management
Coloplast Executive Management Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Anders Lonning-Skovgaard Allan Rasmussen Paul Marcun EVP, CFO EVP, Global Operations EVP, Chronic Care • Born 1972 • Born 1967 • Born 1966 • With Coloplast since 2006 • With Coloplast since 1992
Slide 66: Income statement
Income statement DKKm Q1 2018/19 Q1 2019/20 Change Revenue 4,321 4,712 9% Gross profit 2,903 3,212 11% SG&A costs -1,438 -1,586 10% R&D costs -181 -169 -7% Other operating income/expenses 13 15 15% Operating profit (EBIT) 1,297 1,472 13% Net financial items -10 -54 nm Tax -296 -326 10% Net profit 99
Slide 67: Balance sheet
Balance sheet DKKm 31 Dec 2018 31 Dec 2019 Change Balance, total 12,113 13,223 9% Assets Non-current assets 6,184 6,862 11% Current assets 5,929 6,361 7% of which: Inventories 1,818 1,917 5% Trade receivables 2,894 2,982 3% Restricted cash 74 13 -82% Marketable securities, cash, and cash equivalents
Slide 68: Cash flow
Cash flow DKKm Q1 2018/19 Q1 2019/20 Change EBIT 1,297 1,472 13% Depreciation and amortisation 158 208 32% Change in working capital 166 321 93% Net interest payments -35 -65 86% Paid tax -764 -871 14% Other -50 -35 -30% Cash flow from operations 772 1,030 33% Investments in intangibles -19 -18 -5%
Slide 69: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 11% 2% Mørdrup China 1% Minneapolis Tatabánya Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% Salary - Direct 21% 12% Salary - Indirect Materials (RM &SFG) 8% Innovation & Specialised Pro
Slide 70: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~1,050 • Number of employees in production: ~1,800
Slide 71: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Mankato • Skin care products Sarlat
Slide 72: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Rasmus Sørensen Hannah Katrine Larsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Tel. direct: +45 4911 3376 Tel. direct: +45 4911 1786 Tel. direct: +45 4911 36
Slide 73: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /